RVMD
Revolution Medicines, Inc.
Biotechnology
Market Cap$32.12B
5Y Perf.+391.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RVMD vs ARVN
Revenue, margins, valuation, and 5-year total return — side by side.
ARVN
Arvinas, Inc.
Biotechnology
Market Cap$656M
5Y Perf.-69.2%
RVMD vs ARVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RVMD | ARVN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $32.12B | $656M |
| Revenue (TTM) | $0.00 | $263M |
| Net Income (TTM) | $-1.37B | $-81M |
| Gross Margin | — | 99.5% |
| Operating Margin | — | -44.0% |
| Total Debt | $159M | $9M |
| Cash & Equiv. | $384M | $143M |
RVMD vs ARVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RVMD
ARVN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Revolution Medicine… (RVMD) | 100 | 491.8 | +391.8% |
| Arvinas, Inc. (ARVN) | 100 | 30.8 | -69.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RVMD vs ARVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RVMD leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Arvinas, Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RVMD
Revolution Medicines, Inc.
The Income Pick
RVMD carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.08
- 422.7% 10Y total return vs ARVN's -36.1%
- Lower volatility, beta 1.08, Low D/E 9.7%, current ratio 7.14x
Best for: income & stability and long-term compounding
ARVN
Arvinas, Inc.
The Growth Play
ARVN is the clearest fit if your priority is growth exposure.
- Rev growth -0.3%, EPS growth 53.8%, 3Y rev CAGR 26.0%
- -0.3% revenue growth vs RVMD's -98.6%
- -9.3% ROA vs RVMD's -59.1%, ROIC -22.4% vs -54.3%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARVN | -0.3% revenue growth vs RVMD's -98.6% |
| Quality / Margins | RVMD | 2.8% margin vs ARVN's -30.8% |
| Stability / Safety | RVMD | Beta 1.08 vs ARVN's 1.15 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RVMD | +303.5% vs ARVN's +47.6% |
| Efficiency (ROA) | ARVN | -9.3% ROA vs RVMD's -59.1%, ROIC -22.4% vs -54.3% |
RVMD vs ARVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2022
FY 2025
RVMD vs ARVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRVMDLAGGINGARVN
ARVNArvinas, Inc.
2leads
RVMDRevolution Medicines,…
2leads
6 Total Categories
CATEGORYLEADERvs ARVNMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARVN1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARVN7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
RVMD6/6
Risk & VolatilityBeta, volatility, and downside exposure
RVMD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARVN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ARVN and RVMD operate at a comparable scale, with $263M and $0 in trailing revenue.
| Metric | RVMDRevolution Medici… | ARVNArvinas, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $263M |
| EBITDAEarnings before interest/tax | -$1.4B | -$111M |
| Net IncomeAfter-tax profit | -$1.4B | -$81M |
| Free Cash FlowCash after capex | -$1.1B | -$276M |
| Gross MarginGross profit ÷ Revenue | — | +99.5% |
| Operating MarginEBIT ÷ Revenue | — | -44.0% |
| Net MarginNet income ÷ Revenue | — | -30.8% |
| FCF MarginFCF ÷ Revenue | — | -105.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -84.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -102.7% | -65.1% |
ARVN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RVMD and ARVN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RVMDRevolution Medici… | ARVNArvinas, Inc. |
|---|---|---|
| Market CapShares × price | $32.1B | $656M |
| Enterprise ValueMkt cap + debt − cash | $31.9B | $522M |
| Trailing P/EPrice ÷ TTM EPS | -25.39x | -8.02x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 2.50x |
| Price / BookPrice ÷ Book value/share | 17.61x | 1.53x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RVMD and ARVN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ARVN leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
ARVN delivers a -14.3% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-83 for RVMD. ARVN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RVMD's 0.10x. On the Piotroski fundamental quality scale (0–9), ARVN scores 4/9 vs RVMD's 1/9, reflecting mixed financial health.
| Metric | RVMDRevolution Medici… | ARVNArvinas, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -83.2% | -14.3% |
| ROA (TTM)Return on assets | -59.1% | -9.3% |
| ROICReturn on invested capital | -54.3% | -22.4% |
| ROCEReturn on capital employed | -53.0% | -16.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.10x | 0.02x |
| Net DebtTotal debt minus cash | -$225M | -$134M |
| Cash & Equiv.Liquid assets | $384M | $143M |
| Total DebtShort + long-term debt | $159M | $9M |
| Interest CoverageEBIT ÷ Interest expense | -81.62x | — |
ARVN leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RVMD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RVMD five years ago would be worth $52,093 today (with dividends reinvested), compared to $1,625 for ARVN. Over the past 12 months, RVMD leads with a +303.5% total return vs ARVN's +47.6%. The 3-year compound annual growth rate (CAGR) favors RVMD at 83.5% vs ARVN's -25.4% — a key indicator of consistent wealth creation.
| Metric | RVMDRevolution Medici… | ARVNArvinas, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +91.2% | -10.5% |
| 1-Year ReturnPast 12 months | +303.5% | +47.6% |
| 3-Year ReturnCumulative with dividends | +518.1% | -58.4% |
| 5-Year ReturnCumulative with dividends | +420.9% | -83.8% |
| 10-Year ReturnCumulative with dividends | +422.7% | -36.1% |
| CAGR (3Y)Annualised 3-year return | +83.5% | -25.4% |
RVMD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
RVMD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RVMD is the less volatile stock with a 1.08 beta — it tends to amplify market swings less than ARVN's 1.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 97.0% from its 52-week high vs ARVN's 70.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RVMDRevolution Medici… | ARVNArvinas, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.08x | 1.15x |
| 52-Week HighHighest price in past year | $155.70 | $14.51 |
| 52-Week LowLowest price in past year | $34.00 | $5.90 |
| % of 52W HighCurrent price vs 52-week peak | +97.0% | +70.7% |
| RSI (14)Momentum oscillator 0–100 | 64.2 | 47.4 |
| Avg Volume (50D)Average daily shares traded | 3.0M | 820K |
RVMD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RVMD as "Buy" and ARVN as "Buy". Consensus price targets imply 26.7% upside for ARVN (target: $13) vs 2.5% for RVMD (target: $155).
| Metric | RVMDRevolution Medici… | ARVNArvinas, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $154.80 | $13.00 |
| # AnalystsCovering analysts | 22 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +14.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARVN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). RVMD leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallRevolution Medicines, Inc. (RVMD)Leads 2 of 6 categories
Loading custom metrics...
RVMD vs ARVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RVMD or ARVN a better buy right now?
Analysts rate Revolution Medicines, Inc.
(RVMD) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RVMD or ARVN?
Over the past 5 years, Revolution Medicines, Inc.
(RVMD) delivered a total return of +420. 9%, compared to -83. 8% for Arvinas, Inc. (ARVN). Over 10 years, the gap is even starker: RVMD returned +422. 7% versus ARVN's -36. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RVMD or ARVN?
By beta (market sensitivity over 5 years), Revolution Medicines, Inc.
(RVMD) is the lower-risk stock at 1. 08β versus Arvinas, Inc. 's 1. 15β — meaning ARVN is approximately 6% more volatile than RVMD relative to the S&P 500. On balance sheet safety, Arvinas, Inc. (ARVN) carries a lower debt/equity ratio of 2% versus 10% for Revolution Medicines, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — RVMD or ARVN?
On earnings-per-share growth, the picture is similar: Arvinas, Inc.
grew EPS 53. 8% year-over-year, compared to -66. 2% for Revolution Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RVMD or ARVN?
Revolution Medicines, Inc.
(RVMD) is the more profitable company, earning 0. 0% net margin versus -30. 8% for Arvinas, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVMD leads at 0. 0% versus -43. 8% for ARVN. At the gross margin level — before operating expenses — ARVN leads at 98. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RVMD or ARVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RVMD or ARVN better for a retirement portfolio?
For long-horizon retirement investors, Revolution Medicines, Inc.
(RVMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 08), +422. 7% 10Y return). Both have compounded well over 10 years (RVMD: +422. 7%, ARVN: -36. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RVMD and ARVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.